Alberto Nakauma
@albertonakauma.bsky.social
Bioinformatics | ErasmusMC, Rotterdam, the Netherlands.
Bladder Cancer, Predictive Markers, Immunotherapy, Tumor Microenvironment and Cancer Evolution.
Bladder Cancer, Predictive Markers, Immunotherapy, Tumor Microenvironment and Cancer Evolution.
Is it time for personalized therapy in patients with metastatic urothelial cancer (mUC)?
In this study, we assessed predictive molecular markers of currently approved therapeutic drugs in mUC and found that they are mutually exclusive with unique molecular characteristics.
In this study, we assessed predictive molecular markers of currently approved therapeutic drugs in mUC and found that they are mutually exclusive with unique molecular characteristics.
April 28, 2025 at 6:32 PM
Is it time for personalized therapy in patients with metastatic urothelial cancer (mUC)?
In this study, we assessed predictive molecular markers of currently approved therapeutic drugs in mUC and found that they are mutually exclusive with unique molecular characteristics.
In this study, we assessed predictive molecular markers of currently approved therapeutic drugs in mUC and found that they are mutually exclusive with unique molecular characteristics.